Literature DB >> 12134946

Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?

Fuxing Tang1, Kazutoshi Horie, Ronald T Borchardt.   

Abstract

PURPOSE: To investigate whether Madin-Darby canine kidney cells transfected with the human MRP2 gene (MDCK-MRP2) are a good model of the human intestinal mucosa.
METHODS: MRP2 expression in Caco-2 cells was compared with the expression of this efflux transporter in MDCK-wild type (MDCK-WT) and MDCK-MRP2 cells using Western blotting methods. The polarized efflux activities of MRP2 in the MDCK-MRP2, MDCK-WT. MDCK cells transfected with the human MDR1 gene (MDCK-MDR1), and Caco-2 cells were compared using vinblastine as a substrate. Apparent Michaelis-Menten constants (K(M), Vmax) for the efflux of vinblastine in Caco-2 and MDCK-MRP2 cells were determined in the presence of GF120918 (2 microM), which inhibits P-glycoprotein but does not affect MRP2. Apparent inhibitory constants (K(I)) of known substrates/inhibitors of MRP2 were determined by measuring their effects on the efflux of vinblastine in these cell lines.
RESULTS: MDCK-MRP2 cells expressed higher levels of MRP2 than MDCK-WT and Caco-2 cells as measured by Western blotting technique. Two isoforms of MRP2 expressed in Caco-2 and MDCK cells migrated at molecular weights of 150 kD and 190 kD. In MDCK-MRP2 cells, the 150 kD isoform appeared to be overexpressed. MDCK-MRP2 cell monolayers exhibited higher polarized efflux of vinblastine than Caco-2 and MDCK-WT cell monolayers. K(M) values for vinblastine in Caco-2 and MDCK-MRP2 cells were determined to be 71.8+/-11.6 and 137.3+/-33.6 microM. respectively, and Vmax values were determined to be (0.54+/-0.03 and 2.45+/-0.31 pmolcm(-2)s(-1), respectively. Known substrates/inhibitors of MRP2 showed differences in their ability to inhibit vinblastine efflux in Caco-2 cells as compared to MDCK-MRP2 cells
CONCLUSIONS: These data suggest that MDCK-MRP2 cells overexpress only the 150 kD isoform of MRP2. The 190 kD isoform, which was also found in Caco-2 cells and MDCK-WT cells, was present in MDCK-MRP2 cells but not over expressed. The apparent kinetics constants and affinities of some MRP2 substrates were different in Caco-2 cells and MDCK-MRP2 cells. These differences in substrate activity could result from differences in the relative expression levels of the MRP2 isoforms present in Caco-2 cells and MDCK-MRP2 cells and/or differences in the partitioning of substrates in these two cell membrane bilayers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134946     DOI: 10.1023/a:1016192413308

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

Review 1.  Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane.

Authors:  J Ferté
Journal:  Eur J Biochem       Date:  2000-01

2.  The application of cell culture systems in drug discovery and development.

Authors:  R Borchardt
Journal:  J Drug Target       Date:  1995       Impact factor: 5.121

3.  Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.

Authors:  C Tanaka; R Kawai; M Rowland
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

4.  Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats.

Authors:  C G Dietrich; D R de Waart; R Ottenhoff; I G Schoots; R P Elferink
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

Review 5.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

Authors:  J König; A T Nies; Y Cui; I Leier; D Keppler
Journal:  Biochim Biophys Acta       Date:  1999-12-06

Review 6.  Multidrug-resistance phenotype in Chinese hamster ovary cells.

Authors:  V Ling; N Kartner; T Sudo; L Siminovitch; J R Riordan
Journal:  Cancer Treat Rep       Date:  1983-10

7.  Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B.

Authors:  A T Nies; T Cantz; M Brom; I Leier; D Keppler
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

9.  Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.

Authors:  K I Hosoya; K J Kim; V H Lee
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

10.  Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells.

Authors:  R Evers; G J Zaman; L van Deemter; H Jansen; J Calafat; L C Oomen; R P Oude Elferink; P Borst; A H Schinkel
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

View more
  27 in total

1.  Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Authors:  Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

2.  Transport studies with 5-aminosalicylate.

Authors:  Hua-Wen Xin; Matthias Schwab; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2006-08-30       Impact factor: 2.953

3.  The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

Authors:  Thuy Thanh Tran; Aditya Mittal; Tanya Aldinger; Joseph W Polli; Andrew Ayrton; Harma Ellens; Joe Bentz
Journal:  Biophys J       Date:  2004-10-22       Impact factor: 4.033

4.  Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells.

Authors:  Yun-Xia Li; Liang-Hong Ye; Xue-Hua Jiang; Cheng Peng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-20       Impact factor: 2.441

5.  Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.

Authors:  Kishore Cholkar; Hoang M Trinh; Aswani Dutt Vadlapudi; Zhiying Wang; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2015-04-06       Impact factor: 2.671

Review 6.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

7.  Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Authors:  Konstantin Kuteykin-Teplyakov; Carlos Luna-Tortós; Kamila Ambroziak; Wolfgang Löscher
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

8.  Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.

Authors:  Mitesh Patel; Ye Sheng; Nanda K Mandava; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2014-09-26       Impact factor: 5.875

9.  An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.

Authors:  Brendan M Johnson; William N Charman; Christopher J H Porter
Journal:  AAPS PharmSci       Date:  2002

10.  Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.

Authors:  Barbara J Brennan; Agnès Poirier; Sebastian Moreira; Peter N Morcos; Petra Goelzer; Renée Portmann; Jiney Asthappan; Christoph Funk; Patrick F Smith
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.